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ABSTRACT
Objective To test the effectiveness of a comprehensive
specific care plan in decreasing the rate of functional
decline in patients with mild to moderate Alzheimer’s
disease compared with usual care in memory clinics.
Design Cluster randomised trial.
Setting 50 memory clinics in France.
Participants Patients with Alzheimer’s disease (mini-
mental state examination score 12-26). 1131 patients
were included: 574 from 26 clinics in the intervention
group, and 557 from 24 clinics in the usual care (control)
group. Memory clinics were the unit of randomisation.
Intervention The intervention included a comprehensive
standardised twice yearly consultation for patients and
their caregivers, with standardised guidelines for the
management of problems identified during the
assessment.
Main outcome measures The primary outcome measure
was change on the Alzheimer’s Disease Cooperative
Study-activities of daily living scale assessed at 12 and
24 months. Secondary outcome measures were the rate
of admission to institutional care and mortality.
Results At two years the assessment was completed by
58.4% (n=335) of patients in the intervention group and
61.6%(n=343)inthecontrolgroup.Therateoffunctional
declineattwoyearsdidnotdifferbetweenthegroups.The
annual rate of change on the Alzheimer’s Disease
Cooperative Study-activities of daily living was estimated
at −5.73 (95% confidence interval −6.89 to −4.57) in the
intervention group and −5.96 (−7.05 to −4.86) in the
control group (P=0.78).
Conclusion A comprehensive specific care plan in
memory clinics had no additional positive effect on
functional decline in patients with mild to moderate
Alzheimer’s disease. Future research should aim to
determine the effects of more direct involvement of
general practitioners.
Trial registration ClinicalTrials.gov NCT00480220.
INTRODUCTION
Severalauthoritativegroupshavepublishedconsensus
guidelinesforthecareofpatientswithAlzheimer’sdis-
ease and suggested regular follow-up, with evaluation
and management of behavioural disturbances,
psychoses,anddepression;activemonitoringandsup-
port of the caregiver’s emotional and physical health;
and consideration of treatment with specific drugs.
1-4
Theguidelinesarebasedmostlyonthescientificlitera-
ture. They also include some empirical guidelines; for
example, on the frequency of follow-up assessments.
However, the literature reveals some serious deficits
in the quality of patient management in clinical
practice.
56
Randomised trials of interventions aiming to
improve outcomes for patients with dementia are
few, and those that do exist have reported limited
impacts in primary and residential care.
7-9 Because of
the multifaceted nature of Alzheimer’s disease, com-
prehensive, guideline based interventions for demen-
tiacarewouldseemtobeawellsuitedapproach.Some
questions remain, however, about the setting in which
follow-up and comprehensive assessments should be
carried out (primary care versus memory clinics), as
well as the feasibility and real impact of these guide-
lines. To our knowledge, no large scale interventional
studies integrating a comprehensive, guideline based,
interventionforcareofpatientswithdementiainmem-
ory clinics have been carried out to date.
We carried out a cluster randomised trial at national
level to test the effectiveness of a comprehensive spe-
cific care plan in decreasing the rate of functional
decline in community dwelling patients with mild to
moderate Alzheimer’s disease compared with usual
care in memory clinics.
METHODS
Our studywasa nationwidetrialusing a clusterrando-
miseddesigntocompareaninterventiongroupreceiv-
ingacomprehensivespecificcareplanforAlzheimer’s
disease with a control group receiving usual care.
Memory clinics in university or general hospitals con-
stituted the unit of randomisation, with patients as the
unitofanalysis.Throughtheuseofthisdesignwemini-
mised the risk of contamination between patients
because our intervention concerned doctor practice.
Patients in the intervention group were evaluated
everysixmonthsattheclinic,withsupplementarycon-
sultations if considered necessary by the doctor.
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tioner about the care plan after each visit. Patients in
the control group were evaluated annually. Unrest-
ricted by the study protocol the doctor in charge of
the patient determined the frequency of other consul-
tations between these visits. Patients in the control
group were managed according to each centre’s usual
practice. We obtained written informed consent from
the patients and their caregivers before beginning the
protocol specific procedures. The trial is reported
according to the consolidated standards of reporting
trials statement
10 and its extensions to cluster rando-
mised trials
11 and to non-drug interventions.
12
Participants
The centres were memory clinics in university or gen-
eral hospitals. The centres selected were considered to
have sufficient expertise in both the diagnosis and the
management of Alzheimer’s disease and sufficient
recruitmentcapacitiesforthisstudy.Weaskeddoctors
in eachcentre toincludeconsecutivepatientswhomet
the criteria of the National Institute of Neurological
and Communicative Disorders and Stroke/Alzheimer
Disease and Related Disorders Association
13 for prob-
ableor possibleAlzheimer’sdisease,witha mini-men-
tal state examination
14 score between 12 and 26.
Participants were required to be living in the commu-
nity, not participating in any other research pro-
gramme, and to have a caregiver.
Investigators in the university hospitals were asked
to recruit the first 30 eligible patients who agreed to
take part in the study, and in the general hospitals the
first 20 patients.
Generation of allocation sequence
Allocation was based on clusters rather than patients,
and the sequence was concealed until interventions
were assigned. The nature of the intervention meant
thatneithercareprovidersnorpatientscouldbeblinded
to the intervention received. Allocation to intervention
was based on a randomisation procedure stratified by
hospital teaching status (university or general hospital),
specialty of the centre (neurology, psychiatry, or geria-
tric medicine), and membership to a previous national
Alzheimer’s disease research programme network.
15
We decided on this stratification to minimise imbal-
ancesacrosscentres.Acomputergeneratedrandomisa-
tionprocedurewasusedbyastatisticianindependentof
the centres (Toulouse University).
Intervention
The specific care plan for Alzheimer’s disease was
developed by a multidisciplinary working group (neu-
rologists, geriatricians, psychiatrists, and general prac-
titioners) mandated by the French Ministry of Health
as part of the French government’s first plan of action
for Alzheimer’s disease in 2001. It was based on data
from the scientific literature
1-316-18 and on the personal
experience of members of the working group, taking
intoaccounttheopinionsandexperienceoftheFrench
Alzheimer Association, representatives of the medical
and social sectors, and members of care teams.
The intervention comprised a standardised twice
yearly consultation for patients and their caregivers,
as well as standardised guidelines for the management
of any identified problems (see web extra).
19
Step 1
Because of the high level of complications throughout
the course of Alzheimer’s disease, we highlighted the
necessity of comprehensive standardised evaluations
every six months in memory clinics, including cogni-
tive and non-cognitive assessment. As part of the spe-
cific care planthe evaluation covered the patients’ and
caregivers’ knowledge of the disease; functional
dependency; progression of cognitive decline; review
ofdrugs,includingcholinesteraseinhibitorsandmem-
antine; nutritional status; gait disorders and walking
capacities;behaviouralsymptoms;caregivers’psycho-
logical and physical health; and legal questions about
thesafetyofthepatient.Weusedthemini-mentalstate
examination
14 to measure cognitive decline, the activ-
itiesofdailyliving
20andinstrumentalactivitiesofdaily
living
21 scales to measure functional capacities and the
levelofhelprequiredfortheseactivitiesbythepatient,
the mini nutritional assessment
22 to assess nutritional
status, the neuropsychiatric inventory to evaluate
behavioural disturbances,
23 and the one leg balance
test
24 to measure gait disorders. In addition, we used
the Zarit burden interview to evaluate the burden on
caregivers.
25
Step 2
For each area assessed we outlined a standardised
management protocol that could be initiated when
necessary, based on the results of the comprehensive
assessment. Full details of these protocols are avail-
able at http://cm2r.enamax.net/onra/images/stories/
fiches_plasa.pdfandsummarisedinthewebextra.The
use of these protocols as well as other care strategies
initiated by the doctor was recorded every six months
using a standardised form (see web extra).
The specific care plan for Alzheimer’s disease
mainly focused on non-drug interventions, except for
the item on specific drugs.For each area evaluated,we
designed different types of supporting material. Writ-
ten material was intended for the investigator and his
or her team and reviewed the details of each inter-
vention (evaluation tools and their interpretation, and
the various possibilities of non-drug and, if appropri-
ate,drugmanagement).Thestudyteamalsoproduced
a CD-ROMabout the care plan,includingall the tools
and the care management plan. This served as a
resource for the training of study investigators and
was supplied to each of the centres in the intervention
group. A second package of written support material
was intended for the caregivers and patients’ relatives,
to improve their knowledge and understanding of the
disease and to offer solutions to any problems. These
documents also gave telephone or email contacts of
available support groups and services.
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training session on the specific care plan during a col-
lective meeting before the recruitment period. A sec-
ond training session was planned one year after the
beginningofthestudy.Theaimofthetrainingsessions
was to standardise practices and the use of assessment
tools between centres and to present standardised care
guidelines for each aspect of the disease evaluated.
Usual care
Memory clinics in France were implemented at first to
helpgeneralpractitionerstodiagnoseAlzheimer’sdis-
ease. During the study period, usual care in these
clinics could be summarised as diagnosis with no sys-
tematicfollow-up(unlesspatientsmadeappointments)
or an annual consultation (usually involving a mini-
mental state examination).
Inthistrialweaskeddoctorsinthememoryclinicsin
the control arm to provide their patients with usual
care. At the end of the study all documents used in the
interventionarmweremadeavailabletothesedoctors.
Outcome measures
This study (PLASA, Plan de Soin et d’Aide dans la
maladie d’Alzheimer or “specific care and assistance
plan for Alzheimer disease”) tested the primary
hypothesis that the specific care plan would decrease
the decline in functional capacities in patients with
mild to moderate Alzheimer’s disease, as measured
on the Alzheimer’s Disease Cooperative Study-activ-
itiesofdailylivingscale.
26Thistoolisacaregiverrated
questionnaire of 23 items assessing functional capaci-
ties,withscoresrangingfrom0to78;the highestscore
represents full functioning with no impairment. The
questionnaire was administered to the entire cohort at
inclusion and at the follow-up visits at one and two
years. The secondary outcome measures were the
rate of admission to institutional care and mortality.
Sample size
Our primary hypothesis was that patients in the inter-
ventiongroupwouldhavealowerlevelofdependency
at 24 months compared with patients in the control
group. We considered an effect size of 0.3 to be a sig-
nificant benefit in the intervention group—that is, 0.3
standard deviations less functional decline, as indi-
cated by the change in score on the Alzheimer’s Dis-
ease Cooperative Study-activities of daily living scale,
in the intervention group compared with the control
group. In our original power calculations, we deter-
mined that a sample size of 240 participants in each
group would result in 90% power to detect such a dif-
ference using a two tailed test with an α level of 0.05.
Taking into account the estimated rate of attrition in
patients with dementia,
2728 we planned to recruit 600
patients within each group. In our sample size calcula-
tion we did not take into account the clustering effect
induced by the design (randomisation of clusters).
Indeed,thisstudywasplannedin2001,beforethepub-
lication of the extension of the consolidated standards
of reporting trials statement to cluster randomised
trials.
11Nevertheless,thestatisticalanalysiswascarried
outasrecommendedbytheseinternationalguidelines.
Statistical analysis
The primary analysis was done on an intention to treat
basis—thatis,includedallrandomisedparticipants.We
used both an imputation of mean value and a more
complex approach (longitudinal mixed model) that
does not impute data in the case of missing outcomes.
As we computed the Alzheimer’s Disease Coopera-
tive Study-activities of daily living scores by adding
item responses, data were missing at the level of both
items and scores. If five or fewer items were missing,
we derived the score from non-missing items and
reweighted the score to recover its true range, if more
than five items were missing, we considered the score
as missing. We then carried out the primary analysis
using two statistical strategies, both done in agreement
withtheintentiontotreatprinciple.Firstly,weassessed
the primary outcome by consideringthe crude change
in the Alzheimer’s Disease Cooperative Study-activ-
ities of daily living score—that is, the score at
24 months minus the score at baseline. A missing
score was then handled by imputing the mean value
(estimated from available data) of the group to which
thepatientwasallocated.Wethenusedamixedmodel
toanalysedata,thustakingintoaccountthecorrelation
within patients and the clustering effect. Secondly, we
used a longitudinal mixed model to analyse the
24 memory clinics in control group
(557 patients)
26 memory clinics in intervention group
(574 patients)
12 month assessment
Assessed (n=414)
Did not attend (n=40)
12 month assessment
Assessed (n=430)
Did not attend (n=37)
Memory clinics randomised (n=60)
50 memory clinics, 1131 patients
Declined to participate, before patients recruited (n=10)
Lost to follow-up (n=18)
Dropouts (n=89):
  Refused to participate (n=22)
  Progression of disease (n=7)
  Admitted to institutional care (n=4)
  Caregiver reasons (n=4)
  Other (n=26)
  Died (n=26)
Lost to follow-up (n=5)
Dropouts (n=98):
  Refused to participate (n=22)
  Progression of disease (n=11)
  Admitted to institutional care (n=9)
  Caregiver reasons (n=2)
  Other (n=29)
  Died (n=25)
24 month assessment
Assessed (n=343)
Did not attend (n=44)
24 month assessment
Assessed (n=335)
Did not attend (n=42)
Lost to follow-up (n=2)
Dropouts (n=88):
  Refused to participate (n=22)
  Progression of disease (n=5)
  Admitted to institutional care (n=4)
  Caregiver reasons (n=5)
  Other (n=22)
  Died (n=30)
Lost to follow-up (n=6)
Dropouts (n=61):
  Refused to participate (n=12)
  Progression of disease (n=3)
  Admitted to institutional care (n=6)
  Caregiver reasons (n=2)
  Other (n=20)
  Died (n=18)
Flow of participants through study
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 8primary outcome for data at baseline and at 12 and
24 months, which took into account the two levels of
correlation: between repeated observations of indivi-
dual patients and between patients within centres. In
this second approach, we did not replace missing
scores on the Alzheimer’s Disease Cooperative
Study-activities of daily living scale. The statistical
model was then used to assess available data only.
Foreachgroupweestimatedtheintraclasscorrelation
coefficient. We used Cox marginal models to assess
time toadmissiontoinstitutionalcareanddeath,taking
into account the clustering effect. Statistical analyses
were carried out using SAS software version 9.1.
RESULTS
Sixty centres initially agreed to participate in this trial.
Ten centres (three in the intervention group, seven in
thecontrolgroup)subsequentlywithdrewtheirconsent,
afterrandomisationandbeforetheinclusionofpatients.
Thus, 26 memory clinics (10 in university hospitals, 16
in general hospitals) were randomised to the inter-
vention group and 24 memory clinics (10 in university
hospitals, 14 in general hospitals) to the control group
(figure). Overall, 1131 patients were recruited in these
50 memory clinics between June 2003 and July 2005.
Table 1 lists the baseline characteristics of the cen-
tres and participants by treatment group. The groups
werewellbalanced.Dementiawasmildtomoderateas
shown by an overall mean mini-mental state examina-
tion score of 19.7 (SD 4.0). Acetylcholinesterase inhi-
bitorswerewidelyprescribed;79.0%(893/1131)ofthe
entirecohortwasreceivingthematbaselinebeforethe
first visit.
Intotal,58.4%(n=335)ofpatientsintheintervention
group and 61.6% (n=343) in the control group were
assessed at the two year follow-up visit. Death was the
mainreasonforearlystoppingofthestudy(56ininter-
vention group, 43 in control group). The reasons for
stoppingdidnotdiffersignificantlybetweenthegroups
at 24 months.
Disease progression and main outcome measures
Functional decline did not differ significantly between
thetwogroupsoverthetwoyearsoffollow-up,regard-
less of the method used for data analysis (table 2). The
annual decrease in the Alzheimer’s Disease Coopera-
tive Study-activities of daily living score in the control
groupwasestimatedat−5.96(95%confidenceinterval
−7.05to−4.86)inthecontrolgroupand−5.73(−6.89to
−4.57) in the intervention group (P=0.78; table 2).
After imputation of group mean values for missing
data, the intraclass correlation coefficient for the inter-
vention group was 0.093 (95% confidence interval
0.042 to 0.193) and for the control group was 0.091
(0.040 to 0.193).
The risk of being admitted to institutional care or
mortality did not differ significantly between the inter-
ventiongroupcomparedwiththecontrolgroupattwo
years(admissiontoinstitutionalcare,hazardratio0.95,
95% confidence interval 0.67 to 1.36, P=0.79; mortal-
ity, 0.80, 0.51 to 1.25, P=0.32). For the 221 cases
admitted to institutional care the mean time to admis-
sion did not differ between the groups: 371.2 (SD
196.0) days in the intervention group compared with
368.1(SD210.8)daysinthecontrolgroup(P=0.9088).
The reasons for admission did, however, differ
between the groups. Patients in the control group
were mostly admitted because of worsening medical
conditions (61.5% v 38.5% in intervention group)
whereaspatientsintheinterventiongroupweremostly
admittedduetoreasonsrelatedtocaregivers(70.59%v
29.41% in control group; P=0.0046).
Table 3 summarises progression of the disease, as
measured by the standardised tools. As a result of the
study methodology, these data were only collected in
the intervention group. At two years the decline in
activities of daily living was −1.14 (95% confidence
interval −1.27 to −1.02) and in instrumental activities
of daily living was −1.86 (−2.07 to −1.65).
Table 4shows the frequency of use of the standar-
disedcareprotocols.Intheinterventiongroupatbase-
line a median of six protocols were used per patient.
This number tended to decrease during follow-up
(median of three protocols used at both one and two
years).Theuseofprotocolsrelatingtothedisclosureof
the diagnosis and knowledge of the disease decreased
Table 1 |Baseline characteristics of memory clinics, patients with Alzheimer’sd i s e a s e ,a n d
caregivers randomised to a specific care plan for the management of Alzheimer’s disease or
to usual care (control). Values are numbers (percentages) unless stated otherwise
Characteristics
Intervention
group
Control
group
Memory clinics: n=26 n=24
University hospital 10 (39) 10 (42)
General hospital 16 (62) 14 (58)
Member of Alzheimer’s disease research programme network 6 (23) 7 (29)
No (interquartile range) of patients 20 (18-30) 22 (19-27)
Median (interquartile range) time to include first patient (months) 0.7 (0.5-0.8) 0.7 (0.6-0.9)
Patients: n=574 n=557
Mean (SD) age (years) 80.2 (5.9) 80.2 (5.6)
Women 382 (66.5) 395 (70.9)
Median (interquartile range) duration of disease (years) 3 (2-5) 3 (2-5)
Median (interquartile range) time since diagnosis (years) 1 (0-2) 1 (0-2)
Mean (SD) MMSE score (0-30)* 19.5 (3.9) 20.0 (4.1)
Use of cholinesterase inhibitors at baseline 439 (76.5) 454 (81.5)
Median (interquartile range) No of non-dementia related drugs 4 (2-6) 4 (2-5)
Median No (interquartile range) of chronic diseases 2 (1-3) 2 (1-3)
Living arrangements:
Live alone 187 (32.6) 163 (29.3)
Live with spouse 305 (53.1) 289 (51.9)
Other 82 (14.3) 105 (18.8)
Caregivers: n=574 n=557
Mean (SD) age (years) 64.6 (13.7) 65.1 (13.6)
Women 380 (66.2) 339 (61.0)
Live with patient 309 (54.0) 332 (59.8)
Spouse of patient 271 (47.2) 278 (49.9)
Child of patient 255 (44.4) 234 (42.0)
Other relationship with patient 48 (8.4) 45 (8.1)
MMSE=mini-mental state examination.
*Higher scores represent better function.
RESEARCH
page 4 of 8 BMJ | ONLINE FIRST | bmj.comnoticeably during follow-up. A similar situation was
seenforprotocolsrelatingtomanagementofnutrition,
probablyduetothestabilityofnutritionalstatusinthis
group during follow-up. Behavioural problems
increased by about 1.6 points on the neuropsychiatric
inventory scale during the two years, but the use of
protocols relating to such problems decreased over
time: 31.8% (182/574) at baseline and 21.9% (73/335)
at two years. In line with the increase in functional
dependency, the use of protocols for functional
decline, respite care and admission to institutional
care increased during the study.
DISCUSSION
The results of the primary intention to treat analysis of
this trial showed no difference in the rate of functional
decline, as measured by the Alzheimer’s Disease
Cooperative Study-activities of daily living scale,
between patients with mild to moderate Alzheimer’s
disease randomised to a specific care plan and those
randomised to usual care. To our knowledge, this is
the first nationwide randomised clinical trial to test
the effectiveness of guideline based care interventions
for Alzheimer’s disease delivered in memory clinics.
We chose to carry out this trial in memory clinics
becauseinmanycountries,memoryclinicswithmulti-
disciplinary teams have been established to facilitate
the early detection and management of dementia.
Although some claim that these clinics merely pre-
scribe and monitor drug treatment, such clinics are
becoming increasingly integrated into standard care
for dementia in many countries. Memory clinics are
also more knowledgeable about the management of
complex conditions associated with their specialty.
After randomisation of the centres, the intervention
andcontrolgroupswerewellbalancedatbaseline.The
annualrateofchangeinAlzheimer’sDiseaseCoopera-
tive Study-activities of daily living scores was −5.73 in
the intervention group compared with −5.96 in the
control group. This rate of progression remains glob-
ally similar to the changes seen in most patients
enrolled in placebo groups of clinical trials.
29 A phase
II trial testing the efficacy of tarenflurbil reported an
annualrateofchangeinAlzheimer’sDiseaseCoopera-
tive Study-activities of daily living score of −8.31 at
12 months in patients with Alzheimer’s disease rando-
mised to the placebo group.
30 As in our study, most of
thepatientsintheplacebogroup(97%)inthetarenflur-
bil trial were users of acetylcholinesterase inhibitors.
Another study reported a deterioration of the Alzhei-
mer’sDiseaseCooperativeStudy-activitiesofdailyliv-
ing score of 6.95 points at 12 months in 281 patients in
the placebo group of a study evaluating the efficacy of
growthhormonesecretagogue (71.2%wereusinganti-
dementia drugs at inclusion).
31 The statistical analyses
inthesestudieswere similartoours,usinganintention
to treat method. It must be noted, however, that we
included patients regardless of age or comorbidities,
Table 2 |Mean scores on Alzheimer’s Disease Cooperative Study-activities of daily living (ADCS-ADL) scale at baseline and at
12 and 24 months. Values are means (standard deviations) unless stated otherwise
Variables
ADCS-ADL score (0-78) Crude
change or
estimate P values Baseline 12 months 24 months
Descriptive data*:
Intervention group 53.0 (15.6); n=548 49.4 (17.6); n=328 43.4 (18.4); n=224 ——
Control group 51.1 (16.3); n=546 46.7 (17.1); n=315 42.4 (18.1); n=257 ——
Analysis using imputation of group mean values
for missing data†:
Intervention group (n=574) 53.0 (15.2) 49.5 (13.4) 43.4 (11.6) −9.6 (15.1)‡—
Control group (n=557) 51.1 (16.2) 46.5 (14.2) 42.0 (13.0) −9.1 (15.5)‡ 0.990
Analysis with no imputation for missing data§:
Group effect (intervention v control) ——— 1.157 0.46
Time effect (years) ——— −5.956 <0.001
Interaction group×time ——— 0.226 0.78
*Only patients with scores.
†Missing data handled by imputing mean value of group to which patients were allocated plus analysis using mixed model, taking into account
clustering effect.
‡Score at 24 months minus score at baseline.
§Mixed model taking into account both longitudinal nature of data and correlation induced by randomisation of clusters. Intervention effect assessed
through interaction term that expresses how intervention influences time effect. Annual decrease for ADCS-ADL score was thus −5.96 in control group
versus −5.73 in intervention group.
Table 3 |Results of assessments in intervention group during follow-up. Values are means
(standard errors)
Mixed model Baseline (n=574) 12 months (n=430) 24 months (n=335)
ADL score (0-6)* 5.35 (0.06); n=574 4.79 (0.07); n=428 4.21 (0.09); n=331
IADL score (0-8)* 4.26 (0.17); n=573 3.18 (0.17); n=415 2.40 (0.18); n=320
MMSE score (0-30)* 19.44 (0.18); n=574 17.90 (0.23); n=415 15.75 (0.29); n=326
MNA score (0-30)† 23.87 (0.22); n=571 23.30 (0.22); n=423 22.73 (0.25); n=324
NPI score (0-144)‡ 18.26 (1.20); n=573 19.05 (1.17); n=425 19.85 (1.26); n=329
Zarit burden interview
score (0-88)‡
24.14 (0.92); n=573 26.62 (0.93); n=423 29.10 (1.06); n=324
MMSE=mini-mental state examination; ADL=activities of daily living; IADL=instrumental activities of daily living;
MNA=mini nutritional assessment; NPI=neuropsychiatric inventory.
*Higher scores represent better function.
†Higher scores represent better nutritional status.
‡Higher scores represent worse symptoms.
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teria. Our trial was a pragmatic trial as defined by pre-
vious investigators.
32 Our population is therefore
probably closer to a “real world” situation. In another
randomised controlled trial, the researchers tested the
effectiveness of a collaborative care model to improve
thequalityofcareforpatientswithAlzheimer’sdisease
in primary care.
7 One hundred and fifty three patients
were randomised. For one year the team, led by an
advanced practice nurse working with the patients’
family caregiver, used standard protocols to identify,
monitor, and treat behavioural and psychological
symptoms of dementia, stressing non-drug manage-
ment in the intervention group. The researchers
showed a significant improvement in behavioural
and psychological symptoms of dementia in this
group. However, cognitive and functional decline did
not differ between the groups. The annual rate of
change in Alzheimer’s Disease Cooperative Study-
activities of daily living scores reported by researchers
in their control group was −4.2 at 12 months, but the
last observation carried forward method was used in
their analysis, which is a potential source of bias.
Indeed,the last observationcarried forwardtechnique
assumes that patients remain stable over time from the
timeofdropout,whichisunlikelyinachronicprogres-
sive condition such as Alzheimer’s disease. This tech-
nique therefore underestimates the rate of decline and
some researchers are beginning to doubt this type of
analysis in the specialty of dementia.
33 We used both
an imputation of mean value and a more complex
approach (longitudinal mixed model), which does not
impute data in the case of missing outcomes.
Strengths and weaknesses of the study
This work was a national multicentre study, which
enabled the follow-up of a population of patients with
Alzheimer’s disease living in both urban and rural
(through the general hospitals) environments. In
France, as only specialists are allowed to initiate treat-
ments for dementia there is no real difference between
patientswithAlzheimer’sdiseasefollowedinthesecen-
tres and patients followed in other clinical settings. We
must,however,stressthatthispopulationwasnotrepre-
sentative of all patients with Alzheimer’s disease
becauseweincludedonlycommunitydwellingpatients
with an identified caregiver. Regarding the selection of
patients within centres, we asked eachcentre toinclude
all consecutive outpatients presenting to the centre and
meeting the study inclusion criteria during the study
period.Theinclusionperiodtooklongerthanexpected.
Despite the time spent on administrative issues that
delayed the opening of some centres, we cannot com-
pletely eliminate the possibility that some investigators
did not strictly select all consecutive eligible patients.
This deviation was probably most often related to time
constraints:aninvestigatorwho seesseveralpotentially
eligible patients may decide to include only the first
owing to lack of time. Also, it is possible that investiga-
tors selected a priori those patients who were more
likely to be compliant to the study protocol, especially
as the investigators knew the type of intervention they
had to provide. However secondary bias associated
with this type of selection is probably not a problem in
ourstudygiventhefactthatpatientsinbothgroupswere
comparable at baseline.
Some limitations must be discussed when inter-
preting the lack of effect of the intervention in our
study. The first is a contamination between groups
due to the long duration of the study and recruitment
period.In2004,theFrenchgovernmentreleasedasec-
ond plan of action for Alzheimer’s disease, which
emphasised the broad implementation of memory
clinics as well as structured follow-up of patients. To
investigate the potential effects of this on the study
results, we recovered post hoc the characteristics of
the frequency of follow-up and management proce-
dures in memory clinics from the control arm. The
results indicated that most of the memory clinics pro-
posed regular follow-up during the trial. In fact, a visit
at six months was organised in 18 of the 24 centres,
with systematic evaluation of the mini-mental state
examination carried out by all centres (dependency
was evaluated in a standardised manner in 12 of the
18 centres). The six other centres systematically car-
ried out an annual consultation, with, in all cases stan-
dardised evaluations of the mini-mental state
examinationandofdependency.Theotherevaluation
tools were rarely used.
The second limitation concerns the adherence to
and diversity of programme recommendations.
Reductions in adherence to the interventional proto-
cols would be expected to reduce the effectiveness of
the interventions. Althoughthe investigators recorded
the frequency of use of the standardised protocols, it
was difficult to assess overall adherence to the inter-
ventionbecauseofitscomplexityandmultifacetednat-
ure. Due to the diversity of the intervention, although
the data collection form relative to the intervention
protocols was standardised, the choice of the type of
Table 4 |Frequency of use and type of care management protocols in intervention group
during follow-up. Values are numbers (percentages) unless stated otherwise
Protocols
Baseline
(n=574)
12 months
(n=430)
24 months
(n=335)
Median (interquartile range) No used per patient 6 (4-9) 3 (1-6) 3 (1-5)
Type:
Disclosure of diagnosis 392 (68.3) 23 (5.4) 5 (1.5)
Verification of patient’s knowledge of the disease 415 (72.4) 37 (8.6) 7 (2.1)
Verification of caregivers’ knowledge of the disease 466 (81.5) 207 (48.4) 156 (46.7)
Nutritional status 223 (38.9) 115 (26.9) 79 (23.7)
Exercise training 260 (45.4) 147 (34.4) 104 (31.1)
Gait disorders and walking capacities 151 (26.4) 87 (20.3) 71 (21.3)
Functional dependency 91 (15.9) 115 (26.9) 92 (27.5)
Behavioural symptoms (non-drug or drug related) 182 (31.8) 114 (26.6) 73 (21.9)
Depression 178 (31.1) 81 (18.9) 53 (15.9)
Sleep disorders 108 (18.9) 58 (13.6) 28 (8.4)
Home care services 218 (38.2) 138 (32.2) 93 (27.8)
Respite care 86 (15.0) 71 (16.6) 69 (20.7)
Admission to institutional care 45 (7.9) 41 (9.6) 45 (13.5)
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were at the discretion of the doctor. Moreover, we do
not know if the proposed management strategies were
adequately implemented at home and how receptive
caregivers or general practitioners were to our written
instructions. Furthermore, assessors were not blinded
tointerventionstatus;blindingismoredifficultinnon-
drug trials.
34 Finally, we did not take into account the
clustering effect in our sample size calculation. Data
were, however, analysed taking into account this clus-
tering effect and we can consider that lack of power
probably did not result in the non-significant differ-
ence between groups.
Conclusions
In this randomised clinical trial of 1131 community
dwelling older patients with Alzheimer’s disease, we
could find no clear benefit of comprehensive evalua-
tion and targeted management every six months in
memory clinics for reducing long term functional
decline. This finding underlines the fact that this kind
of broad intervention does not convey benefit in activ-
ities of daily living and may have little public health
value. Alzheimer’s disease is a complex and heteroge-
neous condition. Consequently, to have a beneficial
effect on disease progression it may be that inter-
ventions must be targeted towards patients at particu-
lar risk of decline or we may need to develop a more
effective intervention and ensure that it is correctly
implemented in all patients. This study suggests that
the contribution of advice to caregivers and general
practitioners alone is not sufficient. Future research is
neededtodeterminewhetherfunctionaldeclinecanbe
improvedbymoredirectinvolvementofgeneralprac-
titioners or by using case manager programmes.
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